Dr. George Solomon
Critical Care Medicine (Critical Care Medicine (Internal Medicine) Physician)
- Medicare participating
At a glance
- Medical school
- University of Alabama School of Medicine (2007)
- Years since graduation
- 19
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 296
Licensed in Alabama since 2009, according to the Alabama Board of Medical Examiners and Medical Licensure Commission. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2007Medical school: University of Alabama School of Medicine
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Critical Care Medicine (Internal Medicine) Physician primary
AL license 29339 (first issued 2009; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- University of Alabama Hospital Birmingham, AL
Medical groups
- University of Alabama Health Services Foundation, PC (2,814 clinicians)
- Champion Sports Medicine Birmingham, LLC (176 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 296
- Services billed
- 644
- Patients’ average age
- 71
| Service | Times | Patients |
|---|---|---|
| Test to measure expiratory airflow and volume | 230 | 227 |
| Test to examine how well the lungs exchange gases | 157 | 156 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 112 | 41 |
| Test to determine lung volumes using gas dilution or washout | 77 | 77 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 72 | 27 |
| Established patient office or other outpatient visit, 30-39 minutes | 50 | 43 |
| Established patient office or other outpatient visit, 40-54 minutes | 23 | 20 |
| Critical care, first 30-74 minutes | 15 | 11 |
| Hospital discharge day management, more than 30 minutes | 14 | 14 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Azithromycin Other prescribers in Birmingham, AL | 144 |
| Albuterol Sulfate Hfa (albuterol sulfate) Other prescribers in Birmingham, AL | 90 |
| Trikafta (elexacaftor/tezacaftor/ivacaft) | 81 |
| Prednisone Other prescribers in Birmingham, AL | 50 |
| Fluconazole Other prescribers in Birmingham, AL | 30 |
| Montelukast Sodium Other prescribers in Birmingham, AL | 26 |
| Fluticasone Propionate Other prescribers in Birmingham, AL | 25 |
| Fluticasone-Salmeterol (fluticasone propion/salmeterol) Other prescribers in Birmingham, AL | 22 |
| Levofloxacin Other prescribers in Birmingham, AL | 19 |
| Breo Ellipta (fluticasone/vilanterol) Other prescribers in Birmingham, AL | 19 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 5 companies reported 23 payments worth $4,129 in total to this clinician.
| AstraZeneca Pharmaceuticals LP | $3,222 |
|---|---|
| Insmed, Inc. | $436 |
| Electromed, Inc. | $352 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $105 |
| Abbott Laboratories | $14.40 |
| Consulting Fee | $3,222 |
|---|---|
| Food and Beverage | $907 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP Dec 22, 2025 | Consulting Fee | $3,222 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $8,010 in research payments for these studies, mostly to the institutions running them.
- Study to Evaluate ALIS (Amikacin Liposome Inhalation Suspension) in Participants With Nontuberculous Mycobacterial Lung Infection Caused by Mycobacterium Avium Complex
Insmed, Inc. · Completed · NCT04677569 - A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIR…
Boehringer Ingelheim International GmbH
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.